RADNOR, Pa., June 08, 2026 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in the Goldman Sachs 47th Annual Global Healthcare Conference being held in Miami on June 8-10, 2026.
| Goldman Sachs 47th Annual Global Healthcare Conference | |
| Date: | Tuesday, June 9, 2026 |
| Time: | 2:40pm ET |
| Format: | Fireside Chat |
| Webcast Link | |
A live webcast of this fireside chat can also be accessed on the “News & Events” page in the Investors section of the Mineralys Therapeutics website.
About Mineralys
Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, Twitter and Bluesky.
Contact:
Investor Relations
investorrelations@mineralystx.com
Media Relations
Melyssa Weible
Elixir Health Public Relations
Email: mweible@elixirhealthpr.com



Đề xuất
InsurInnovator Connect Vietnam 2026 to Address Key Developments in Vietnam’s Insurance Market
TCEB Unveils Six New MICE Cities – Expanding Thailand’s Network to 16 Destinations
Why Japanese Retail Giants Like Aeon and Uniqlo Keep Investing Heavily in Vietnam
Rising Investments in Advanced Batteries Drive Global Lithium-Sulfur Battery Market Growth
Rising Investments in Advanced Batteries Drive Global Lithium-Sulfur Battery Market Growth
Network Modernization and High-Speed Connectivity Drive TD-LTE Ecosystem Market Growth